Credit Suisse’s Exact Sciences EXAS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $67.5M | Sell |
976,932
-12,712
| -1% | -$804K | 0.06% | 292 |
|
|
2023
Q4 | $73.2M | Buy |
989,644
+2,067
| +0.2% | +$135K | 0.07% | 282 |
|
|
2023
Q3 | $67.4M | Buy |
987,577
+31,585
| +3% | +$2.68M | 0.07% | 297 |
|
|
2023
Q2 | $89.8M | Sell |
955,992
-203,534
| -18% | -$15.9M | 0.09% | 231 |
|
|
2023
Q1 | $78.6M | Sell |
1,159,526
-406,956
| -26% | -$26.2M | 0.08% | 250 |
|
|
2022
Q4 | $77.6M | Sell |
1,566,482
-15,296
| -1% | -$625K | 0.08% | 250 |
|
|
2022
Q3 | $51.4M | Buy |
1,581,778
+4,564
| +0.3% | +$188K | 0.06% | 359 |
|
|
2022
Q2 | $62.1M | Buy |
1,577,214
+3,844
| +0.2% | +$206K | 0.06% | 317 |
|
|
2022
Q1 | $110M | Sell |
1,573,370
-521,297
| -25% | -$38.1M | 0.09% | 223 |
|
|
2021
Q4 | $163M | Sell |
2,094,667
-40,229
| -2% | -$3.55M | 0.09% | 224 |
|
|
2021
Q3 | $204M | Buy |
2,134,896
+248,728
| +13% | +$26.3M | 0.11% | 168 |
|
|
2021
Q2 | $234M | Buy |
1,886,168
+63,634
| +3% | +$7.59M | 0.12% | 159 |
|
|
2021
Q1 | $240M | Buy |
1,822,534
+524,476
| +40% | +$71.8M | 0.12% | 165 |
|
|
2020
Q4 | $172M | Sell |
1,298,058
-336,867
| -21% | -$40.7M | 0.08% | 248 |
|
|
2020
Q3 | $167M | Buy |
1,634,925
+352,544
| +27% | +$30.4M | 0.1% | 204 |
|
|
2020
Q2 | $111M | Sell |
1,282,381
-312,135
| -20% | -$24.9M | 0.08% | 251 |
|
|
2020
Q1 | $92.5M | Buy |
1,594,516
+795,849
| +100% | +$64.6M | 0.08% | 243 |
|
|
2019
Q4 | $73.9M | Buy |
798,667
+283,153
| +55% | +$24.9M | 0.05% | 384 |
|
|
2019
Q3 | $46.6M | Sell |
515,514
-44,889
| -8% | -$5.11M | 0.04% | 484 |
|
|
2019
Q2 | $66.2M | Sell |
560,403
-120,817
| -18% | -$12.2M | 0.06% | 337 |
|
|
2019
Q1 | $59M | Buy |
681,220
+50,164
| +8% | +$4.27M | 0.05% | 360 |
|
|
2018
Q4 | $39.8M | Buy |
631,056
+101,730
| +19% | +$6.98M | 0.04% | 459 |
|
|
2018
Q3 | $41.8M | Buy |
529,326
+53,356
| +11% | +$3.48M | 0.04% | 490 |
|
|
2018
Q2 | $28.5M | Sell |
475,970
-281,186
| -37% | -$15.1M | 0.03% | 647 |
|
|
2018
Q1 | $30.5M | Buy |
757,156
+305,388
| +68% | +$14.9M | 0.03% | 637 |
|
|
2017
Q4 | $23.7M | Buy |
451,768
+235,551
| +109% | +$12.6M | 0.02% | 794 |
|
|
2017
Q3 | $10.2M | Sell |
216,217
-18,925
| -8% | -$762K | 0.01% | 1238 |
|
|
2017
Q2 | $8.32M | Sell |
235,142
-341,846
| -59% | -$10.6M | 0.01% | 1304 |
|
|
2017
Q1 | $13.6M | Buy |
576,988
+242,342
| +72% | +$4.8M | 0.01% | 1044 |
|
|
2016
Q4 | $4.47M | Buy |
334,646
+36,654
| +12% | +$592K | ﹤0.01% | 1733 |
|
|
2016
Q3 | $5.53M | Buy |
297,992
+18,688
| +7% | +$329K | 0.01% | 1585 |
|
|
2016
Q2 | $3.42M | Buy |
279,304
+138,562
| +98% | +$1.04M | ﹤0.01% | 1912 |
|
|
2016
Q1 | $949K | Sell |
140,742
-235,478
| -63% | -$1.51M | ﹤0.01% | 2769 |
|
|
2015
Q4 | $3.47M | Buy |
376,220
+121,706
| +48% | +$1.13M | ﹤0.01% | 1876 |
|
|
2015
Q3 | $4.58M | Buy |
254,514
+35,852
| +16% | +$824K | 0.01% | 1624 |
|
|
2015
Q2 | $6.5M | Buy |
218,662
+25,400
| +13% | +$638K | 0.01% | 1537 |
|
|
2015
Q1 | $4.26M | Buy |
193,262
+8,847
| +5% | +$224K | ﹤0.01% | 1797 |
|
|
2014
Q4 | $5.06M | Sell |
184,415
-24,237
| -12% | -$590K | ﹤0.01% | 1747 |
|
|
2014
Q3 | $4.04M | Sell |
208,652
-275
| -0.1% | -$5.04K | ﹤0.01% | 1925 |
|
|
2014
Q2 | $3.56M | Buy |
208,927
+110,716
| +113% | +$1.52M | ﹤0.01% | 2251 |
|
|
2014
Q1 | $1.39M | Buy |
98,211
+17,128
| +21% | +$231K | ﹤0.01% | 2824 |
|
|
2013
Q4 | $952K | Buy |
81,083
+32,674
| +67% | +$375K | ﹤0.01% | 3320 |
|
|
2013
Q3 | $571K | Buy |
48,409
+8,193
| +20% | +$105K | ﹤0.01% | 3418 |
|
|
2013
Q2 | $559K | Buy |
+40,216
| New | +$437K | ﹤0.01% | 3230 |
|
Other funds holding EXAS
AIM
Credit Suisse's EXAS Position: Q1 2024 in Review
Credit Suisse reduced its Exact Sciences (EXAS) stake by 1.3% in Q1 2024, selling an estimated $804K and leaving 976,932 shares worth $67.5M. The position accounts for 0.06% of the portfolio, ranked #292.
Credit Suisse first reported a position in EXAS in Q2 2013 and has held it in 44 quarters since. The position peaked at $240M in Q1 2021. 627 funds tracked by Wall St. Rank hold EXAS as of Q1 2024.
- Credit Suisse held 976,932 shares of Exact Sciences worth $67.5M as of Q1 2024.
- Credit Suisse sold 12,712 Exact Sciences shares in Q1 2024, an estimated $804K.
- Exact Sciences made up 0.06% of Credit Suisse's portfolio in Q1 2024, its #292 holding.
- Credit Suisse first reported a position in Exact Sciences in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Exact Sciences position peaked at $240M in Q1 2021.
- 627 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.